OTC: MDCLF - MedinCell S.A.

Yield per half year: 0%
Dividend yield: 0.00%
Sector: Healthcare

Share chart MedinCell S.A.


About MedinCell S.A.

MedinCell S.A. develops various therapeutic solutions in France. It develops solutions based on BEPO, a technology for long-acting injectable products based on proprietary copolymers and a biocompatible solvent, which solubilizes or suspends the active pharmaceutical ingredients.

more details
The company's products in development include mdc-IRM, a risperidone extended-release injectable suspension completed Phase III trial for use in the treatment of schizophrenia; mdc-CWM, a sustained-release formulation of celecoxib in Phase III trials for use in the treatment of reduction of postoperative pain & inflammation; and mdc-TJK, a subcutaneous injection in Phase III trials for use in the treatment of schizophrenia. Its product candidates in preclinical trials, such as mdc-ANG, an antipsychotic product for use in the treatment of schizophrenia; mdc-TTG for Covid-19 and its variants; mdc-GRT for use in organ transplant; mdc-WWM for contraception; mdc-STM for use in malaria; mdc-KPT for use in acute pain for pets; and mdc-IRM for use in neuroscience. The company was incorporated in 2003 and is based in Jacou, France.

Industry Biotechnology
Sector Health Care
Валюта usd
Валюта отчета eur
Сайт https://www.medincell.com
Цена ао 6.98
Change price per day: 0% (6.976)
Change price per week: 0% (6.976)
Change price per month: 0% (6.976)
Change price per 3 month: 0% (6.976)
Change price per half year: 0% (6.976)
Change price per year: +0.0043% (6.9757)
Change price per 3 year: -28.08% (9.7)
Change price per year to date: 0% (6.976)

Underestimation

Title Value Grade
P/S 19.97 1
P/BV -4.48 0
P/E 0 0
EV/EBITDA -11.95 0
Total: 2.63

Efficiency

Title Value Grade
ROA, % -75.54 0
ROE, % 60.25 10
Total: 3.33

Dividends

Title Value Grade
Div yield, % 0 0
DSI 0 0
Total: 0

Debt

Title Value Grade
Debt/EBITDA -3.17 10
Total: 9.4

Growth impulse

Title Value Grade
Yield Revenue, % 221.18 10
Yield Ebitda, % 3.76 1
Yield EPS, % -35.02 0
Total: 2.4

Institutions Volume Share, %
American Funds Insurance Ser-Global Small Capitalization Fund 397121 1.58



Head Job title Payment Year of birth
Mr. Christophe Douat Chief Executive Officer & Director 427.7k 1966 (59 years)
Mr. Franck Pouzache Chief People Officer & Member of the Management Board 216.57k
Julie Alimi Head of Legal N/A
Mr. David Heuze Head of Communications N/A
Mr. Adolfo Lopez-Noriega Head of Research & Development N/A
Mr. Sebastien Enault Chief Business Officer N/A
Ms. Helen Martin Head of Alliance & Project Management N/A
Ms. Quiterie De Beauregard Head of Global Health Development N/A
Dr. Richard Malamut M.D. Chief Medical Officer N/A 1960 (65 years)
Mr. Stephane Postic Chief Financial Officer

Address: France, Jacou, 3 rue des Frères Lumière - open in Google maps, open in Yandex maps
Website: https://www.medincell.com